Palvella Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.4 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 108.88% -0.40pp
- Institutions
- 244 +1
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 29 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Wesley Kaupinen | Chief Executive Officer | 5.65% |
| George Jenkins | Independent Chairperson | 0.91% |
| Todd Davis | Independent Director | 0.77% |
| Elaine Heron | Independent Director | 0.37% |
| Matthew Korenberg | CFO, Corporate Secretary & Treasurer | 0.01% |
| Christopher Kiritsy | Independent Director | 0.00% |
| BVF Partners L.P. | -- | -- |
| Tadd Wessel | Independent Director | -- |
| John Doux | Independent Director | -- |
| Matthew Pauls | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-10 | Jeffrey Martini | Chief Scientific Officer | Derivative Exercise and Sale | -12,500 | $7.53–172.12 |
| 2026-11-09 | Jeffrey Martini | Chief Scientific Officer | Intent to Sell (Form 144) | -50,000 | $174.08 |
| 2026-10-20 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,313 | $7.14–126.19 |
| 2026-10-13 | George Jenkins | Independent Chairperson | Automatic Disposition | -27,500 | $121.14–136.44 |
| 2026-10-12 | George Jenkins | Independent Chairperson | Intent to Sell (Form 144) | -27,500 | $134.38 |
| 2026-09-15 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–153.24 |
| 2026-09-14 | George Jenkins | Independent Chairperson | Automatic Disposition | -27,500 | $149.38–153.10 |
| 2026-09-10 | George Jenkins | Independent Chairperson | Intent to Sell (Form 144) | -27,500 | $150.39 |
| 2026-09-01 | Christopher Kiritsy | Independent Director | Derivative Exercise and Sale | -313 | $127.20–157.00 |
| 2026-08-18 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–156.77 |
| 2026-07-14 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–150.25 |
| 2026-06-28 | Matthew Pauls | Director | Other Derivative Acquisition | +6,000 | $154.84 |
| 2026-06-16 | Kathleen Goin | Chief Operating Officer | Derivative Exercise and Sale | -4,302 | $7.14–112.23 |
| 2026-06-11 | Matthew Korenberg | CFO, Corporate Secretary & Treasurer | Derivative Exercise and Retained | +1,000 | $13.60 |
| 2026-06-09 | George Jenkins | Independent Chairperson | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Elaine Heron | Independent Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Todd Davis | Independent Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Christopher Kiritsy | Independent Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | Tadd Wessel | Independent Director | Other Derivative Acquisition | +3,000 | $102.19 |
| 2026-06-09 | John Doux | Independent Director | Other Derivative Acquisition | +3,000 | $102.19 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Palvella Therapeutics discussion 0 comments